Sort   by:  
 Page size 
MetabolomicsTargeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib, have significantly improved outcomes in ovarian cancer (OC); however, therapy resistance remains a major clinical challenge. Here, we showed that glutamine metabolism was upregulated in PARPi-resistant OC cells and identified the g...

2026-04-08 | MTBLS14072 | MetaboLights
MetabolomicsMetabolic analysis of Parp1 ko/wt Saline & Bleo Mouse Lung Fiboblasts and Human IPF & Normal Lung Fiboblasts (Part 2)
Not available
ORGANISM(S): Mus musculus 
ST000275 | MetabolomicsWorkbench
MetabolomicsMetabolic analysis of Parp1 ko/wt Saline & Bleo Mouse Lung Fiboblasts and Human IPF & Normal Lung Fiboblasts (Part 3)
Not available
ORGANISM(S): Mus musculus 
ST000183 | MetabolomicsWorkbench
ProteomicsHXMS on PARP1+DNA+HPF1 to study the dynamics of PARP1
The project is about studying the dynamics of PARP1 when bound to DNA and HPF1.
ORGANISM(S): Homo sapiens (Human) 
2022-02-17 | PXD026580 | Pride
Hxms Parp1 Hpf1 Dna 
ProteomicsNovel modifications of PARP inhibitor veliparib increase PARP1 binding to DNA breaks
The project is about studying the dynamics of PARP1 when bound to DNA and veliparib derivatives.
ORGANISM(S): Homo sapiens (Human) 
2024-03-19 | PXD047072 | Pride
Parp1 Parpi Hdx-ms Allostery 
TranscriptomicsNotch/HES1-mediated PARP1 activation: A cell-type specific mechanism for tumor suppression
Notch signaling plays both oncogenic and tumor suppressor roles, depending on cell type. In contrast to T cell acute lymphoblastic leukemia (T-ALL), where Notch activation promotes leukemogenesis, induction of Notch signaling in B-ALL leads to growth arrest and apoptosis. The Notch target Hairy/Enha...
ORGANISM(S): Homo sapiens 
2011-12-12 | E-GEOD-26366 | biostudies-arrayexpress
ProteomicsPARP1 auto-modification promotes faithful Okazaki fragment processing and limits replication fork speed
Poly(ADP-ribose) polymerase (PARP) inhibitors have proven their efficacy for treating tumors defective in homologous recombination via synthetic lethality. In response to DNA breaks, PARP1 is the primary ADP-ribosylation writer, modifying itself (auto-modification) and other proteins to facilitate r...
ORGANISM(S): Homo sapiens (Human) 
2025-10-02 | PXD066033 | Pride
Parp1 Ptm Okazaki fragment Adp-ribosylation Dna replication 
ProteomicsNucleophagy removes cytotoxic trapped PARP1
Poly (ADP-ribose) polymerase inhibitors (PARPi) induce cytotoxicity in homologous recombination repair (HRR)-deficient cancers by causing PARP1 to become trapped on chromatin, resulting in irreparable replication-associated DNA damage. Cancer cells commonly develop resistance to PARPi, with a recent...
ORGANISM(S): Homo sapiens (Human) 
2026-04-15 | PXD071389 | Pride
Hdx-ms 
ProteomicsPARP1 proximity proteomics reveals interaction partners at stressed replication forks
PARP1 mediates poly-ADP-ribosylation of proteins on chromatin in response to different types of DNA lesions. PARP inhibitors are used for the treatment of BRCA1/2-deficient breast, ovarian, and prostate cancer. Loss of DNA replication fork protection is proposed as one mechanism that contributes to ...
ORGANISM(S): Homo sapiens (Human) 
2022-10-11 | PXD037154 | Pride
Parp1 Proximity proteomics Ipond Olaparib Adp-ribosylation Tpx2 Replication stress 
Proteomicscomparative mass spectrometry analysis of the PARP1 and PAR-PARP1 interactomes
To investigate the functional outcome of PARP1 activation, we performed a pull-down assay coupled with comparative mass spectrometry (MS) analysis to identify proteins that are specifically associated with PAR-PARP1.
ORGANISM(S): Homo sapiens (Human) 
2022-02-14 | PXD031109 | Pride
Human Parp1 Par-parp1 
Sort   by:  
 Page size